

Sam Schulman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6469297/publications.pdf>

Version: 2024-02-01

344
papers

40,661
citations

12303

69
h-index

2500

196
g-index

353
all docs

353
docs citations

353
times ranked

26052
citing authors

#	ARTICLE	IF	CITATIONS
1	Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 446-458.	1.5	15
2	Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 399-409.	1.0	3
3	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. <i>Annals of Internal Medicine</i> , 2022, 175, 29-35.	2.0	33
4	Prevention of the Postthrombotic Syndrome with Anticoagulation: A Narrative Review. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1255-1264.	1.8	10
5	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 129.	3.8	37
6	Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12650.	1.0	7
7	Adherence to apixaban for extended thromboprophylaxis after major abdominal or pelvic surgery for cancer: A prospective cohort study. <i>Journal of Surgical Oncology</i> , 2022, 126, 386-393.	0.8	2
8	2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. <i>Stroke</i> , 2022, 53, 101161STR000000000000407.	1.0	363
9	Recent Advances in Thrombosis and Hemostasis—Part VIII. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 405-406.	1.5	1
10	Pathogenetic and prognostic significance of inflammation and altered ADAMTS-13/vWF axis in patients with severe COVID-19. <i>Obstetrics, Gynecology and Reproduction</i> , 2022, 16, 228-243.	0.2	5
11	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	1.9	100
12	Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2226-2236.	1.9	23
13	New-Onset Atrial Fibrillation in Sepsis: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 018-025.	1.5	14
14	Clinical history of cancer-associated splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 983-991.	1.9	12
15	Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 561-570.	1.0	0
16	Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1112-1115.	1.9	8
17	Anticoagulant Treatment of COVID-19 as Early as Possible—Sulodexide and Perspectives. <i>Thrombosis and Haemostasis</i> , 2021, 121, 849-853.	1.8	5
18	Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 709-723.	1.5	11

#	ARTICLE	IF	CITATIONS
19	Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. <i>BMJ, The</i> , 2021, 373, n1205.	3.0	38
20	Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RECOVER study patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2495-2503.	1.9	12
21	Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2618-2628.	1.9	12
22	Recent Advances in Thrombosis and Hemostasis—Part VII. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 621-622.	1.5	3
23	MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e049557.	0.8	3
24	A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 159-167.	1.0	5
25	Pregnancy-related pelvic vein thrombosis. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 627-632.	0.2	0
26	Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2021, 0, .	1.8	3
27	A Phase 3, Randomized, Double-Blinded Study of Four-Factor Prothrombin Complex Concentrate in Patients with Acute Major Bleeding on Direct Oral Anticoagulant Therapy with Factor Xa Inhibitor: The Lex-210 Study. <i>Blood</i> , 2021, 138, 3235-3235.	0.6	0
28	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , 2020, 4, 4693-4738.	2.5	636
29	Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. <i>Journal of the American Heart Association</i> , 2020, 9, e017316.	1.6	18
30	Effect of Direct Oral Anticoagulant, Patient, and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation Study. <i>TH Open</i> , 2020, 04, e255-e262.	0.7	2
31	Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. <i>Blood Advances</i> , 2020, 4, 3520-3527.	2.5	38
32	Is venous thromboembolism a preventable cause of death?. <i>Lancet Haematology,the</i> , 2020, 7, e555-e556.	2.2	5
33	Venous Thromboembolism in COVID-19. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1642-1653.	1.8	54
34	A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. <i>Pilot and Feasibility Studies</i> , 2020, 6, 52.	0.5	8
35	Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 772-776.	1.5	47
36	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206

#	ARTICLE	IF	CITATIONS
37	Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1143-1146.	1.8	30
38	Definition of pulmonary embolism-related death and classification of the cause of death in venous thromboembolism studies: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1495-1500.	1.9	33
39	Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1661-1671.	1.9	10
40	Development of a standardized definition of pulmonary embolism-related death: A cross-sectional survey of international thrombosis experts. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1415-1420.	1.9	7
41	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
42	Anticoagulant therapy for splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1562-1568.	1.9	60
43	Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. <i>Blood Advances</i> , 2020, 4, 1539-1553.	2.5	15
44	Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020, 4, 500-513.	2.5	10
45	Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE ₂ Study. <i>American Journal of Medicine</i> , 2020, 133, 936-945.	0.6	10
46	Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 977-985.	1.5	8
47	Epidural Catheter Use and Further Issues in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 333.	2.6	0
48	Prophylaxis of Venous Thromboembolism in Patients with Infectious Disease. <i>Tuberculosis and Respiratory Diseases</i> , 2020, 83, 255-256.	0.7	0
49	COVID-19, hemostasis disorders and risk of thrombotic complications. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2020, 75, 306-317.	0.2	8
50	Recent Advances in Thrombosis and Hemostasis: Part VI. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 863-864.	1.5	1
51	Deep Vein Thrombosis Diagnosis with D-Dimer Adjusted to Clinical Probability. <i>Blood</i> , 2020, 136, 20-20.	0.6	0
52	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , 2019, 179, 1469.	2.6	283
53	Reply: Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in the management of major bleeding: Methodological issues. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1398-1399.	1.9	0
54	Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. <i>Thrombosis Research</i> , 2019, 182, 12-19.	0.8	10

#	ARTICLE	IF	CITATIONS
55	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 366, l4363.	2.4	177
56	Recent Advances in Thrombosis and Hemostasis—Part V. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 757-759.	1.5	0
57	Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 499-506.	1.9	6
58	Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1144-1152.	1.9	34
59	Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 150-156.	1.5	12
60	Recent Advances in Thrombosis and Hemostasis—Part IV. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 130-131.	1.5	2
61	Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. <i>Blood Advances</i> , 2019, 3, 158-167.	2.5	92
62	Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors. <i>Anesthesiology</i> , 2019, 131, 1153-1165.	1.3	14
63	Diagnosis of Pulmonary Embolism with D-Dimer Adjusted to Clinical Probability. <i>New England Journal of Medicine</i> , 2019, 381, 2125-2134.	13.9	207
64	Treatment of bleeding complications in patients on anticoagulant therapy. <i>Blood</i> , 2019, 133, 425-435.	0.6	65
65	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. <i>Blood</i> , 2018, 131, 2151-2160.	0.6	62
66	Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 282-290.	1.0	32
67	Incidence and risk factors for acute kidney injury in patients with excessive anticoagulation on warfarin: a retrospective study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 557-561.	1.0	10
68	Management of recurrent venous thromboembolism in patients with cancer: A review. <i>Thrombosis Research</i> , 2018, 164, S172-S177.	0.8	17
69	Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 486-495.	1.0	19
70	Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 842-851.	1.8	157
71	Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. <i>American Heart Journal</i> , 2018, 195, 108-114.	1.2	28
72	Oral anticoagulant dosing, administration, and storage: a cross-sectional survey of Canadian health care providers. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 180-185.	1.0	8

#	ARTICLE	IF	CITATIONS
73	Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials. <i>Expert Review of Hematology</i> , 2018, 11, 37-44.	1.0	15
74	Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review. <i>European Respiratory Review</i> , 2018, 27, 180094.	3.0	16
75	Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time. <i>Thrombosis Research</i> , 2018, 171, 62-67.	0.8	4
76	Splanchnic vein thrombosis: what are the long-term risks?. <i>Lancet Haematology</i> , 2018, 5, e431-e432.	2.2	3
77	Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 684-688.	1.0	66
78	Recent Advances in Thrombosis and Hemostasis – Part III. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 312-314.	1.5	3
79	Are NSAIDs Double Trouble?. <i>Journal of the American College of Cardiology</i> , 2018, 72, 268-270.	1.2	6
80	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e176.	1.3	57
81	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. <i>Blood</i> , 2018, 132, 2527-2527.	0.6	4
82	Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts. <i>PLoS ONE</i> , 2018, 13, e0191137.	1.1	16
83	Reasons for Switching from Warfarin to a Direct Oral Anticoagulant: A Retrospective Study. <i>Blood</i> , 2018, 132, 5060-5060.	0.6	0
84	Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding. <i>Chest</i> , 2017, 152, 81-91.	0.4	68
85	Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. <i>Thrombosis Research</i> , 2017, 152, 44-48.	0.8	46
86	Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER®, RE-COVER®, II, and RE-MEDY®, III. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 484-489.	1.0	6
87	How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. <i>Blood</i> , 2017, 129, 3285-3293.	0.6	39
88	Bleeding Complications and Management on anticoagulant therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 886-892.	1.5	10
89	Recent Advances in Thrombosis and Hemostasis – Part II. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 809-810.	1.5	3
90	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, 016950.	0.8	6

#	ARTICLE	IF	CITATIONS
91	Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. <i>Blood</i> , 2017, 130, 1706-1712.	0.6	258
92	Direct Oral Anticoagulants in the Real World. <i>Canadian Journal of Nursing Research</i> , 2017, 49, 105-107.	0.6	5
93	Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. <i>Neurology</i> , 2017, 89, 687-696.	1.5	79
94	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2017, 160, 97-104.	0.8	18
95	Optimal timing of starting thromboprophylaxis for patients with acute spinal cord injury: A survey of Canadian spine surgeons. <i>Thrombosis Research</i> , 2017, 160, 38-40.	0.8	4
96	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2415-2424.	1.8	62
97	Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. <i>Thrombosis and Haemostasis</i> , 2017, 117, 491-499.	1.8	33
98	Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2045-2052.	1.8	36
99	NOACs for treatment of venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1317-1325.	1.8	18
100	Venous thromboembolism: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1219-1229.	1.8	88
101	Acute Unilateral Renal Infarction in the Setting of an Inherited Thrombophilia and Atrial Septal Defect. <i>Case Reports in Hematology</i> , 2017, 2017, 1-3.	0.3	0
102	RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2017, 117, 415-421.	1.8	14
103	Accumulating data on rivaroxaban for venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1840-1840.	1.8	2
104	Matching genes with constitution and environment. <i>Thrombosis and Haemostasis</i> , 2016, 116, 592-594.	1.8	0
105	Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 115, 291-298.	1.8	21
106	Appropriateness of Apixaban Dosing to Prevent Stroke in Patients with Atrial Fibrillation: A Pilot Study. <i>Canadian Journal of Hospital Pharmacy</i> , 2016, 69, 449-453.	0.1	5
107	The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 480-485.	1.8	7
108	Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation. <i>Thrombosis Research</i> , 2016, 145, 143-148.	0.8	16

#	ARTICLE	IF	CITATIONS
109	Periprocedural Management of Direct Oral Anticoagulants. <i>Regional Anesthesia and Pain Medicine</i> , 2016, 41, 127-129.	1.1	18
110	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. <i>Lancet Haematology</i> , 2016, 3, e267-e275.	2.2	55
111	Management of bleeding complications in patients with cancer on DOACs. <i>Thrombosis Research</i> , 2016, 140, S142-S147.	0.8	12
112	Less menorrhagia for women with VTE. <i>Blood</i> , 2016, 127, 1378-1379.	0.6	8
113	Incidence and risk factors for venous thromboembolism in patients with acute spinal cord injury: A retrospective study. <i>Thrombosis Research</i> , 2016, 147, 97-101.	0.8	27
114	Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. <i>European Respiratory Journal</i> , 2016, 48, 1369-1376.	3.1	159
115	Recent Advances in Thrombosis and Hemostasis – Part I. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 805-807.	1.5	3
116	Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER ^Å , RE-COVER ^Å , II, and RE-MEDY ^Å . <i>Vascular Medicine</i> , 2016, 21, 506-514.	0.8	71
117	Update on the Treatment of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 891-898.	1.5	7
118	Treatment of acute pulmonary embolism with dabigatran versus warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 714-721.	1.8	24
119	Management of venous thromboembolism: an update. <i>Thrombosis Journal</i> , 2016, 14, 23.	0.9	31
120	Reply to Dr Lessire et al. <i>Regional Anesthesia and Pain Medicine</i> , 2016, 41, 788.	1.1	2
121	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. <i>Thrombosis Research</i> , 2016, 140, 81-88.	0.8	14
122	Incidence and Risk Factors for Venous Thromboembolism in Patients with Spinal Cord Injury: A Retrospective Study. <i>Blood</i> , 2016, 128, 1440-1440.	0.6	0
123	Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1010-1018.	1.9	77
124	Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. <i>Thrombosis and Haemostasis</i> , 2015, 114, 150-157.	1.8	144
125	Treatment of Venous Thromboembolism with New Oral Anticoagulants According to Patient Risk. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 160-165.	1.5	3
126	Thrombin generation test in children and adolescents with chronic liver disease. <i>Thrombosis Research</i> , 2015, 135, 382-387.	0.8	11

#	ARTICLE	IF	CITATIONS
127	Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 513-519.	1.1	14
128	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. JAMA Internal Medicine, 2015, 175, 1474.	2.6	180
129	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. New England Journal of Medicine, 2015, 373, 823-833.	13.9	951
130	Anticoagulation for stroke prevention in new atrial fibrillation after coronary artery bypass graft surgery. Thrombosis Research, 2015, 135, 841-845.	0.8	7
131	Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves. Journal of Thrombosis and Thrombolysis, 2015, 40, 430-436.	1.0	10
132	Perioperative Management of Dabigatran. Circulation, 2015, 132, 167-173.	1.6	133
133	<scp>d</scp>-Dimer Testing to Select Patients With a First Unprovoked Venous Thromboembolism Who Can Stop Anticoagulant Therapy. Annals of Internal Medicine, 2015, 162, 27-34.	2.0	128
134	Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2015, 3, 347-353.e1.	0.9	28
135	Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. Journal of Thrombosis and Thrombolysis, 2015, 39, 427-433.	1.0	13
136	Graduated compression stockings to treat acute leg pain associated with proximal DVT. Thrombosis and Haemostasis, 2014, 112, 1137-1141.	1.8	48
137	Prolonged Bleeding After Surgery. , 2014, , 151-160.		0
138	When the Rubber Meets the Road: Adherence and Persistence with Nonâ€“Vitamin K Antagonist Oral Anticoagulants and Old Oral Anticoagulants in the Real Worldâ€“A Problem or A Myth ?. Seminars in Thrombosis and Hemostasis, 2014, 40, 852-859.	1.5	17
139	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. Seminars in Thrombosis and Hemostasis, 2014, 40, 099-105.	1.5	39
140	Response to Letter Regarding Article, â€œManagement and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarinâ€œ. Circulation, 2014, 130, e95.	1.6	0
141	Advantages and limitations of the new anticoagulants. Journal of Internal Medicine, 2014, 275, 1-11.	2.7	69
142	Association of Venous Thromboembolism With Hormonal Contraception and Thrombophilic Genotypes. Obstetrics and Gynecology, 2014, 124, 600-609.	1.2	64
143	New oral anticoagulant agents â€“ general features and outcomes in subsets of patients. Thrombosis and Haemostasis, 2014, 111, 575-582.	1.8	58
144	Venous Thromboembolism in Older Adults: A Community-based Study. American Journal of Medicine, 2014, 127, 530-537.e3.	0.6	41

#	ARTICLE	IF	CITATIONS
145	Distal deep vein thrombosis â€“ a benign disease?. <i>Thrombosis Research</i> , 2014, 134, 5-6.	0.8	5
146	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 435-442.	1.0	10
147	Activated prothrombin complex concentrate for dabigatranâ€“associated bleeding. <i>British Journal of Haematology</i> , 2014, 164, 308-310.	1.2	51
148	Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2014, 383, 880-888.	6.3	425
149	Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. <i>Circulation</i> , 2014, 129, 764-772.	1.6	824
150	Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: A randomized trial. <i>Thrombosis Research</i> , 2014, 134, 814-818.	0.8	13
151	Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1254-1259.	1.9	26
152	Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. <i>BMJ Open</i> , 2014, 4, e005674-e005674.	0.8	3
153	Potential antidotes for reversal of old and new oral anticoagulants. <i>Thrombosis Research</i> , 2014, 133, S158-S166.	0.8	37
154	Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. <i>Thrombosis and Haemostasis</i> , 2014, 111, 233-239.	1.8	43
155	Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. <i>Blood</i> , 2014, 124, 1968-1975.	0.6	662
156	Effect of Reversal of Neuromuscular Blockade with Sugammadex <i>versus</i> Usual Care on Bleeding Risk in a Randomized Study of Surgical Patients. <i>Anesthesiology</i> , 2014, 121, 969-977.	1.3	71
157	Systematic Review of Observational Studies Assessing Bleeding Risk in Patients with Atrial Fibrillation Not Using Anticoagulants. <i>PLoS ONE</i> , 2014, 9, e88131.	1.1	11
158	Bleeding and antidotes in new oral anticoagulants. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 191-202.	0.7	84
159	Selective <i>D</i> -Dimer Testing for Diagnosis of a First Suspected Episode of Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2013, 158, 93.	2.0	73
160	Adherence to anticoagulant treatment with dabigatran in a realâ€“world setting. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1295-1299.	1.9	91
161	Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. <i>Circulation</i> , 2013, 128, 2325-2332.	1.6	257
162	Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1203-1210.	0.8	28

#	ARTICLE	IF	CITATIONS
163	Tossing a coin or using common sense. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 432-434.	1.9	2
164	New anticoagulants in atrial fibrillation management. <i>Thrombosis Research</i> , 2013, 131, S63-S66.	0.8	1
165	Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 709-718.	13.9	868
166	Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion. <i>Thrombosis Research</i> , 2013, 131, 300-303.	0.8	2
167	Secondary prevention of venous thromboembolism. <i>BMJ, The</i> , 2013, 347, f5440-f5440.	3.0	5
168	Extended Anticoagulation in Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 2328-2329.	13.9	10
169	Optimal Duration of Anticoagulant Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 141-146.	1.5	4
170	Bile acids and coagulation factors. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 152-158.	0.8	17
171	Anticoagulation Control with Daily Low-Dose Vitamin K to Reduce Clinically Adverse Outcomes and International Normalized Ratio Variability: A Systematic Review and Meta-Analysis. <i>Pharmacotherapy</i> , 2013, 33, 1184-1190.	1.2	9
172	The accuracy of the International Normalized Ratio and the American College of Chest Physicians recommendations on the use of vitamin K to reverse over-anticoagulation: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 566-567.	1.9	0
173	High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. <i>Thrombosis and Haemostasis</i> , 2013, 110, 184-190.	1.8	19
174	American College of Chest Physicians Guidelines for Heparin-Induced Thrombocytopenia: Response. <i>Chest</i> , 2013, 143, 1191.	0.4	1
175	Respiratory Review of 2013: Pulmonary Thromboembolism. <i>Tuberculosis and Respiratory Diseases</i> , 2013, 75, 89.	0.7	6
176	Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 1136-1136.	0.6	6
177	Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 212-212.	0.6	10
178	Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 2375-2375.	0.6	10
179	Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. <i>Blood</i> , 2013, 122, 460-460.	0.6	2
180	Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 582-582.	0.6	13

#	ARTICLE	IF	CITATIONS
181	Perioperative Management Of Patients On Dabigatran – a Prospective Cohort Study. <i>Blood</i> , 2013, 122, 3637-3637.	0.6	0
182	Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. <i>Blood Transfusion</i> , 2013, 11, 533-40.	0.3	14
183	Antithrombotic Therapy. , 2012, , 171-177.		0
184	Treatment of venous thromboembolism with dabigatran. <i>Current Opinion in Pulmonary Medicine</i> , 2012, 18, 410-415.	1.2	14
185	Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 705-713.	0.5	4
186	The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 07-15.	1.5	17
187	Prevention of VTE in Nonsurgical Patients. <i>Chest</i> , 2012, 141, e195S-e226S.	0.4	1,780
188	Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. <i>Chest</i> , 2012, 141, e601S-e636S.	0.4	401
189	Thrombosis is associated with inferior survival in multiple myeloma. <i>Haematologica</i> , 2012, 97, 1603-1607.	1.7	66
190	Prevention of VTE in Orthopedic Surgery Patients. <i>Chest</i> , 2012, 141, e278S-e325S.	0.4	1,723
191	Advances in the management of venous thromboembolism. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 361-377.	0.7	11
192	Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. <i>Thrombosis Research</i> , 2012, 129, 146-151.	0.8	121
193	Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. <i>Thrombosis and Haemostasis</i> , 2012, 108, 493-498.	1.8	55
194	How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. <i>Blood</i> , 2012, 119, 3016-3023.	0.6	226
195	Accuracy and safety of 99mTc-labeled anti-D-dimer (DI-80B3) Fab™ fragments (ThromboView®) in the diagnosis of deep vein thrombosis: A phase II study. <i>Thrombosis Research</i> , 2012, 130, 381-389.	0.8	27
196	Is the network meta-analysis (NETMA) bringing us closer to the truth? Insights from recent antithrombotic drug data. <i>Thrombosis and Haemostasis</i> , 2012, 108, 872-875.	1.8	5
197	Is the warfarin saga over?. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2012, 42, 51-55.	0.2	3
198	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1228-1235.	1.8	24

#	ARTICLE	IF	CITATIONS
199	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2012, 141, e531S-e575S.	0.4	891
200	Treatment and Prevention of Heparin-Induced Thrombocytopenia. Chest, 2012, 141, e495S-e530S.	0.4	860
201	Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. Chest, 2012, 141, 53S-70S.	0.4	213
202	Evidence-Based Management of Anticoagulant Therapy. Chest, 2012, 141, e152S-e184S.	0.4	1,105
203	Pharmacologic tools to reduce bleeding in surgery. Hematology American Society of Hematology Education Program, 2012, 2012, 517-21.	0.9	19
204	Pharmacologic tools to reduce bleeding in surgery. Hematology American Society of Hematology Education Program, 2012, 2012, 517-521.	0.9	27
205	Elevated Risk of Venous but Not Arterial Thrombosis in Waldenström's Macroglobulinemia and Lymphoplasmacytic Lymphoma. Blood, 2012, 120, 1603-1603.	0.6	2
206	Management and Outcomes of Major Bleeding On Dabigatran or Warfarin. Blood, 2012, 120, 19-19.	0.6	7
207	Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etxilate Is Maintained Over 1 Year of Post-Treatment Follow-up. Blood, 2012, 120, 21-21.	0.6	20
208	A Multicenter Randomized Placebo Controlled Trial of Compression Stockings to Prevent the Post-Thrombotic Syndrome After Proximal Deep Venous Thrombosis: The S.O.X. Trial. Blood, 2012, 120, 393-393.	0.6	5
209	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. Blood, 2012, 120, 499-499.	0.6	3
210	Positive Predictive Value of Progressively Elevated D-Dimer Levels in Patients with a Suspected First Deep Vein Thrombosis.. Blood, 2012, 120, 2258-2258.	0.6	1
211	A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery. Drug Safety, 2011, 34, 449-463.	1.4	20
212	Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance. Seminars in Hematology, 2011, 48, 46-54.	1.8	13
213	A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. Thrombosis and Haemostasis, 2011, 105, 232-238.	1.8	9
214	Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ: British Medical Journal, 2011, 342, d3036-d3036.	2.4	315
215	Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood, 2011, 117, 2089-2092.	0.6	17
216	Warfarin Dose Assessment Every 4 Weeks Versus Every 12 Weeks in Patients With Stable International Normalized Ratios. Annals of Internal Medicine, 2011, 155, 653.	2.0	79

#	ARTICLE	IF	CITATIONS
217	Resumption of Oral Anticoagulation After Warfarin-Associated Intracerebral Hemorrhage. <i>Stroke</i> , 2011, 42, 3663-3664.	1.0	15
218	A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). <i>Blood</i> , 2011, 118, 205-205.	0.6	77
219	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. <i>Blood</i> , 2010, 115, 4991-4998.	0.6	204
220	Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 202-204.	1.9	1,826
221	Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 641-650.	1.9	15
222	Direct and indirect costs of management of long-term warfarin therapy in Canada. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2192-2200.	1.9	33
223	New aspects on treatment modalities for thromboembolic episodes. <i>Journal of Internal Medicine</i> , 2010, 268, 109-119.	2.7	3
224	Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. <i>Thrombosis and Haemostasis</i> , 2010, 104, 118-121.	1.8	34
225	Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 652-660.	0.9	76
226	Optimal Timing of Resumption of Warfarin After Intracranial Hemorrhage. <i>Stroke</i> , 2010, 41, 2860-2866.	1.0	186
227	Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range. <i>Thrombosis Research</i> , 2010, 125, 393-397.	0.8	11
228	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2010, 363, 2499-2510.	13.9	2,807
229	Dabigatran Etexilate: Future Directions in Anticoagulant Treatment. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 32S-41S.	0.7	5
230	Haemorrhagic and Thromboembolic Complications versus Intensity of Treatment of Venous Thromboembolism with Oral Anticoagulants. <i>Acta Medica Scandinavica</i> , 2009, 224, 425-430.	0.0	9
231	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , 2009, 84, 579-583.	2.0	28
232	The plasma concentration of activated protein C appears normal in patients with haemophilia. <i>Haemophilia</i> , 2009, 15, 566-570.	1.0	4
233	Postoperative Low Molecular Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 378-382.	0.5	92
234	Getting intimate with the venous thrombus. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1266-1267.	1.9	6

#	ARTICLE	IF	CITATIONS
235	Cervical artery dissection: Pathology, epidemiology and management. <i>Thrombosis Research</i> , 2009, 123, 810-821.	0.8	143
236	Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2009, 361, 2342-2352.	13.9	2,330
237	Rivaroxaban in Orthopedic Surgery – A Change of Paradigm?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 613-620.	0.7	1
238	Oral Vitamin K Versus Placebo to Correct Excessive Anticoagulation in Patients Receiving Warfarin. <i>Annals of Internal Medicine</i> , 2009, 150, 293.	2.0	132
239	Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism.. <i>Blood</i> , 2009, 114, 1-1.	0.6	7
240	Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study.. <i>Blood</i> , 2009, 114, 1872-1872.	0.6	2
241	Anticoagulants for the Treatment of Venous Thromboembolism. <i>Fundamental and Clinical Cardiology</i> , 2009, , 155-170.	0.0	0
242	Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study. <i>Thrombosis Journal</i> , 2008, 6, 15.	0.9	25
243	Validation of a composite score for clinical severity of hemophilia. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1113-1121.	1.9	84
244	Clinical factors influencing the sensitivity to warfarin when restarted after surgery. <i>Journal of Internal Medicine</i> , 2008, 263, 412-419.	2.7	14
245	Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment. <i>Chest</i> , 2008, 133, 257S-298S.	0.4	655
246	Current strategies in prophylaxis and treatment of venous thromboembolism. <i>Annals of Medicine</i> , 2008, 40, 352-359.	1.5	10
247	Determinants of Bleeding Risk in Patients on Antithrombotic and Antifibrinolytic Drugs. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 762-771.	1.5	3
248	Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V. <i>Haematologica</i> , 2008, 93, 1273-1275.	1.7	6
249	Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. <i>Thrombosis and Haemostasis</i> , 2008, 99, 616-622.	1.8	37
250	Extension of anticoagulation after venous thromboembolism - risk factors influencing the decision. <i>Hamostaseologie</i> , 2008, 28, 110-9.	0.9	0
251	Is 3 months the optimum duration of anticoagulation therapy for deep vein thrombosis and pulmonary embolism?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 472-473.	3.3	0
252	The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2007, 147, 766.	2.0	192

#	ARTICLE	IF	CITATIONS
253	Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 657-660.	0.5	28
254	NXY-059 Does Not Affect Bleeding Time in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Phase I Study. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 264-272.	1.0	5
255	Optimal reversal of vitamin K antagonists. <i>Thrombosis Research</i> , 2007, 119, 15-16.	0.8	5
256	Anticoagulants and Their Reversal. <i>Transfusion Medicine Reviews</i> , 2007, 21, 37-48.	0.9	191
257	The onerous task of comparing treatments in inhibitor patients. <i>Thrombosis and Haemostasis</i> , 2007, 98, 710-712.	1.8	2
258	Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. <i>Lancet</i> , The, 2006, 368, 371-378.	6.3	278
259	New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2006, 96, 258-266.	1.8	28
260	Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 734-742.	1.9	416
261	Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. <i>British Journal of Haematology</i> , 2006, 133, 68-77.	1.2	14
262	An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. <i>Haemophilia</i> , 2006, 12, 223-227.	1.0	27
263	Thromboprophylaxis in Medical Patients – Why Not For All?. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 141-145.	0.5	3
264	Can fondaparinux safely prevent the occurrence of venous thromboembolism in acutely ill medical patients?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 358-359.	3.3	1
265	Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. <i>Current Medical Research and Opinion</i> , 2006, 22, 1813-1823.	0.9	14
266	Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 279-290.	2.3	23
267	Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 692-694.	1.9	3,778
268	Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1177-1180.	1.8	24
269	Ximelagatran in the Clinic: Practical Management of Patients. <i>Seminars in Vascular Medicine</i> , 2005, 5, 301-307.	2.1	0
270	A Step Change in Oral Anticoagulation: Lack of Coagulation Monitoring with Ximelagatran. <i>Seminars in Vascular Medicine</i> , 2005, 5, 259-265.	2.1	2

#	ARTICLE	IF	CITATIONS
271	The Role of Ximelagatran in the Treatment of Venous Thromboembolism. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2005, 34, 18-24.	0.5	8
272	Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. Country Review Ukraine, 2005, 7, C34-C40.	0.8	14
273	Recombinant FVIIa in children with liver disease. Thrombosis Research, 2005, 116, 185-197.	0.8	21
274	Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Thrombosis and Haemostasis, 2005, 94, 522-527.	1.8	16
275	Ximelagatran for the secondary prevention of venous thromboembolism. A complementary follow-up analysis of the THRIVE III Study. Thrombosis and Haemostasis, 2005, , .	1.8	5
276	Patient self-management of anticoagulants reduced arterial thromboembolism and adverse effects. ACP Journal Club, 2005, 143, 8.	0.1	0
277	Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study. Thrombosis and Haemostasis, 2005, 94, 820-4.	1.8	10
278	Mutation Analysis in F9 Gene of 17 Families with Haemophilia B from Iran. Haemophilia, 2004, 10, 751-755.	1.0	10
279	Hemorrhagic Complications of Anticoagulant Treatment. Chest, 2004, 126, 287S-310S.	0.4	452
280	Incidence of Recurrent Venous Thromboembolism According to Duration of Vitamin K Antagonists: Results of a Meta-Analysis on Individual Data.. Blood, 2004, 104, 710-710.	0.6	2
281	Limited Protective Effect of the CCR5 Δ 32/CCR5 Δ 32 Genotype on Human Immunodeficiency Virus Infection Incidence in a Cohort of Patients with Hemophilia and Selection for Genotypic X4 Virus. Journal of Infectious Diseases, 2003, 187, 215-225.	1.9	10
282	Care of Patients Receiving Long-Term Anticoagulant Therapy. New England Journal of Medicine, 2003, 349, 675-683.	13.9	216
283	Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran. New England Journal of Medicine, 2003, 349, 1713-1721.	13.9	444
284	Why Is Factor Xa Not a Better Target Than Factor IIa for Therapeutic Inhibition of Coagulation?. Seminars in Thrombosis and Hemostasis, 2003, 29, 033-036.	1.5	3
285	Platelet-leukocyte aggregation under shear stress: Differential involvement of selectins and integrins. Thrombosis and Haemostasis, 2003, 90, 679-687.	1.8	53
286	Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders. Thrombosis and Haemostasis, 2003, 89, 741-6.	1.8	3
287	Low-intensity warfarin therapy prevented recurrent venous thromboembolism. ACP Journal Club, 2003, 139, 42.	0.1	0
288	Low-intensity warfarin therapy prevented recurrent venous thromboembolism. ACP Journal Club, 2003, 139, 42.	0.1	0

#	ARTICLE	IF	CITATIONS
289	Inhibition of Warfarin Activity by Ribavirin. <i>Annals of Pharmacotherapy</i> , 2002, 36, 72-74.	0.9	38
290	Hypofibrinolytic State in HIV-1-Infected Patients Treated With Protease Inhibitor-Containing Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 441-449.	0.9	79
291	Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients?. <i>Blood</i> , 2002, 99, 2271-2272.	0.6	36
292	Pregnancy, Heparin and Osteoporosis. <i>Thrombosis and Haemostasis</i> , 2002, 87, 180-181.	1.8	30
293	Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism. <i>The Hematology Journal</i> , 2002, 3, 311-314.	2.0	3
294	Pregnancy, heparin and osteoporosis. <i>Thrombosis and Haemostasis</i> , 2002, 87, 180-1.	1.8	9
295	Duration of anticoagulants in acute or recurrent venous thromboembolism. <i>Current Opinion in Pulmonary Medicine</i> , 2000, 6, 321-325.	1.2	4
296	Molecular genetic analysis of severe protein C deficiency. <i>Human Genetics</i> , 2000, 106, 646-653.	1.8	13
297	Incidence of Cancer after Prophylaxis with Warfarin against Recurrent Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2000, 342, 1953-1958.	13.9	326
298	Continuous Infusion of Recombinant Factor VIIa in Hemophilic Patients with Inhibitors: Safety, Monitoring, and Cost Effectiveness. <i>Seminars in Thrombosis and Hemostasis</i> , 2000, Volume 26, 0421-0424.	1.5	35
299	Molecular genetic analysis of severe protein C deficiency. <i>Human Genetics</i> , 2000, 106, 646-653.	1.8	37
300	The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene. <i>Thrombosis and Haemostasis</i> , 1999, 81, 684-689.	1.8	209
301	Safety and Efficacy of Continuous Infusion of a Combined Factor VIII von Willebrand Factor (vWF) Concentrate (Haemate-P, C) in Patients with von Willebrand Disease. <i>Thrombosis and Haemostasis</i> , 1999, 81, 229-233.	1.8	43
302	For How Long Should the Treatment with Vitamin K Antagonists Be Maintained?. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1999, 29, 89-90.	0.5	0
303	Optimization of Treatment for Venous Thromboembolism and Prevention of Recurrences. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1999, 29, 79-80.	0.5	0
304	Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. <i>British Journal of Haematology</i> , 1999, 105, 1109-1113.	1.2	258
305	Major surgery seems not to influence HIV disease progression in haemophilia patients. <i>British Journal of Haematology</i> , 1998, 103, 10-14.	1.2	8
306	Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and Death Among Patients with Venous Thromboembolism Following Anticoagulant Therapy. <i>American Journal of Medicine</i> , 1998, 104, 332-338.	0.6	481

#	ARTICLE	IF	CITATIONS
307	Long-Term Prophylaxis in Venous Thromboembolism: LMWH or Oral Anticoagulation?. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1998, 28, 17-21.	0.5	2
308	The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism. New England Journal of Medicine, 1997, 336, 393-398.	13.9	592
309	Coagulation factor concentrates by continuous infusion. Transfusion Medicine Reviews, 1997, 11, 56-63.	0.9	19
310	Optimal Duration of Oral Anticoagulant Therapy in Venous Thromboembolism. Thrombosis and Haemostasis, 1997, 78, 693-698.	1.8	21
311	Increased fetal loss in women with heritable thrombophilia. Lancet, The, 1996, 348, 913-916.	6.3	640
312	Anticoagulation in venous Thrombosis. Journal of the Royal Society of Medicine, 1996, 89, 624-630.	1.1	5
313	Role of Fibrin Sealants in Surgical Procedures on Patients With Hemostatic Disorders. Clinical Orthopaedics and Related Research, 1996, 328, 65-75.	0.7	45
314	The fixed flexed and subluxed knee in the haemophilic child: what should be done?. Haemophilia, 1996, 2, 47-50.	1.0	19
315	Social Support and the Development of Immune Function in Human Immunodeficiency Virus Infection. Psychosomatic Medicine, 1995, 57, 32-36.	1.3	100
316	Continuous Infusion of Factor Concentrates: Review of Use in Hemophilia A and Demonstration of Safety and Efficacy in Hemophilia B. Acta Haematologica, 1995, 94, 35-42.	0.7	27
317	Hepatitis E virus infection in hemophiliacs. Journal of Medical Virology, 1995, 46, 153-156.	2.5	30
318	The feasibility of using concentrates containing factor IX for continuous infusion. Haemophilia, 1995, 1, 103-110.	1.0	26
319	A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism. New England Journal of Medicine, 1995, 332, 1661-1665.	13.9	928
320	Fibrin Sealant in Surgery of Patients with a Hemorrhagic Diathesis. Thrombosis and Haemostasis, 1995, 74, 486-492.	1.8	47
321	Stability of factor VIII concentrates after reconstitution. American Journal of Hematology, 1994, 45, 217-223.	2.0	58
322	Psychosocial Self-Prognosis in Relation to Mortality and Morbidity in Hemophiliacs with HIV Infection. Psychotherapy and Psychosomatics, 1994, 62, 185-192.	4.0	21
323	Coping Style in Relation to the Consumption of Factor Concentrate in HIV-Infected Hemophiliacs during the Years after Their Infection Became Known. Psychotherapy and Psychosomatics, 1994, 61, 205-210.	4.0	0
324	Two different missense mutations at Arg 178 of the protein C (PROC) gene causing recurrent venous thrombosis. Human Genetics, 1992, 89, 685-6.	1.8	9

#	ARTICLE	IF	CITATIONS
325	DDAVP—The Multipotent Drug in Patients With Coagulopathies. <i>Transfusion Medicine Reviews</i> , 1991, 5, 132-144.	0.9	39
326	Effects of factor VIII concentrates on the immune system in hemophilic patients. <i>Annals of Hematology</i> , 1991, 63, 145-151.	0.8	18
327	Heparin, DDAVP and the Bleeding Time. <i>Thrombosis and Haemostasis</i> , 1991, 65, 242-244.	1.8	32
328	Antibodies against Hepatitis C in a Population of Swedish Haemophiliacs and Heterosexual Partners. <i>Scandinavian Journal of Infectious Diseases</i> , 1990, 22, 393-397.	1.5	28
329	No Evidence for Vertical Transmission in Children Born to HIV Seropositive Male Haemophiliacs. <i>Scandinavian Journal of Infectious Diseases</i> , 1988, 20, 141-143.	1.5	0
330	HIV isolation and antigen detection in infected individuals and their seronegative sexual partners. <i>Aids</i> , 1988, 2, 107-112.	1.0	10
331	Pulmonary Hypertension in Hemophilia. <i>Annals of Internal Medicine</i> , 1988, 109, 759.	2.0	14
332	HIV—serology and lymphocyte subsets in relation to therapy and clinical development in haemophiliacs. <i>European Journal of Haematology</i> , 1988, 41, 459-466.	1.1	12
333	HIV Infection in a Defined Population of Swedish Haemophiliacs. <i>Scandinavian Journal of Infectious Diseases</i> , 1987, 19, 159-166.	1.5	8
334	Transmission of HIV Infection to Heterosexual Partners but Not to Household Contacts of Seropositive Haemophiliacs. <i>Scandinavian Journal of Infectious Diseases</i> , 1986, 18, 497-500.	1.5	22
335	Long-term Sequelae of Calf Vein Thrombosis Treated with Heparin or Low-dose Streptokinase. <i>Acta Medica Scandinavica</i> , 1986, 219, 349-357.	0.0	70
336	STUDIES ON THE MEDICAL TREATMENT OF DEEP VEIN THROMBOSIS. <i>Acta Medica Scandinavica</i> , 1985, 218, 3-68.	0.0	8
337	Relationship Between Thromboembolic Complications and Intensity of Treatment During Long-Term Prophylaxis with Oral Anticoagulants Following DVT. <i>Thrombosis and Haemostasis</i> , 1985, 53, 137-140.	1.8	22
338	Local venous infusion of streptokinase in DVT. <i>Thrombosis Research</i> , 1984, 34, 213-216.	0.8	8
339	Hepatitis, Epidemiology and Liver Function in Hemophiliacs in Sweden. <i>Acta Medica Scandinavica</i> , 1984, 215, 249-256.	0.0	17
340	A Comparative Randomized Trial of Low-Dose Versus High-Dose Streptokinase in Deep Vein Thrombosis of the Thigh. <i>Thrombosis and Haemostasis</i> , 1984, 51, 261-265.	1.8	51
341	Intensive Initial Oral Anticoagulation and Shorter Heparin Treatment in Deep Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1984, 52, 276-280.	1.8	25
342	Thermography in the Diagnosis of DVT. <i>Thrombosis and Haemostasis</i> , 1981, 46, 652-654.	1.8	5

#	ARTICLE	IF	CITATIONS
343	Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study. <i>BMJ</i> , The, 0, , e067378.	3.0	10
344	High factor VIII levels and recurrent thromboembolism in patients with and without inflammatory bowel disease: a retrospective comparative study. <i>TH Open</i> , 0, 0, .	0.7	0